Given the rarity of lymphomas, many clinicians are not using radiation therapy appropriately in the frontline setting.

The management of bladder cancer is evolving across the spectrum of disease and stage and this educational activity is extremely valuable to the ASTRO membership.

This activity explores the evolving role of imaging biomarkers in radiotherapy, focusing on their capacity to improve target delineation, systemically predict and monitor treatment responses, and inform personalized clinical decision making on adaptive platforms.

This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC).

Increasing evidence has demonstrated the importance of immunomodulation on tumor control. Radiotherapy, specifically, can produce a multitude of local and systemic immunomodulatory effects, including reprogramming the tumor microenvironment and exposing tumor antigens via in situ vaccination.

Retroperitoneal sarcomas (RPS), a rare subset of soft tissue sarcomas, account for 10-15% of these cases and are distinguished by their substantial size, infiltrative nature, and proximity to vital anatomical structures.

Some patients with soft tissue sarcomas may be inoperable due to medical comorbidity or might decline radical or amputative surgeries due to undesirable functional outcomes.

In contradistinction to many other malignancies, gynecologic cancers continue to rise in incidence and/or mortality. By 2030, endometrial cancer will be one of the top three female cancers, exceeding colon cancer rates.

Each year in the U.S., thousands of pregnant people will be diagnosed with cancer and face the need for radiotherapy.